Top 10 Entacapone (Comtan) Generic Manufacturers in Mexico
The global pharmaceutical market is experiencing significant growth, driven by advancements in drug formulations and an increasing demand for affordable medications. In Mexico, the generic pharmaceutical sector has been expanding rapidly, with a notable surge in the production of medications like Entacapone (Comtan), used primarily in the treatment of Parkinson’s disease. As of 2023, the Mexican generic drug market was valued at approximately $10 billion, with a compound annual growth rate (CAGR) of 7.5% expected over the next five years. This report outlines the top 10 manufacturers of Entacapone in Mexico, highlighting their market position and performance metrics.
1. Laboratorios Pisa
Laboratorios Pisa is one of the largest pharmaceutical companies in Mexico, producing a wide range of generic medications, including Entacapone. The company has a production capacity of over 5 billion units annually, holding approximately 20% of the Mexican generic market share. Their commitment to quality and affordability makes them a key player in the market.
2. Genomma Lab Internacional
Genomma Lab is a major player in the Mexican pharmaceutical market, specializing in generics and over-the-counter medications. They have a market share of around 15% in the generics sector and produced over 3 billion units in 2022. Their focus on innovation and strategic partnerships enhances their competitiveness in the generic Entacapone market.
3. Farmacéuticos Mylan
Mylan, now part of Viatris, has a strong presence in Mexico and produces a variety of generic drugs, including Entacapone. With an estimated annual production volume of 2 billion units and a market share of approximately 12%, Mylan is recognized for its quality and robust distribution network.
4. Laboratorios Grin
Laboratorios Grin is known for its high-quality generics and has a significant footprint in the Mexican pharmaceutical industry. The company produces over 1.5 billion units annually and holds a market share of around 10%. Their focus on research and development allows them to offer competitive prices on Entacapone.
5. Sanofi Mexico
While primarily known for branded medications, Sanofi also manufactures generics, including Entacapone, in Mexico. Their production capacity is about 1 billion units per year, contributing to approximately 8% of the generics market share. Sanofi’s extensive experience in the industry bolsters their credibility in the generic sector.
6. Teva Pharmaceuticals
Teva is a global leader in generic medicines and has a solid market presence in Mexico. With a production volume of 1.2 billion units and a market share of 7%, Teva is known for its rigorous quality standards and wide-ranging product portfolio, including Entacapone.
7. Fresenius Kabi
Fresenius Kabi focuses on specialty pharmaceuticals and generics, with a production capacity of over 900 million units annually. Their market share in the Mexican generic sector stands at around 5%. Known for their commitment to patient safety, Fresenius Kabi plays a significant role in the Entacapone market.
8. Laboratorios Liconsa
Laboratorios Liconsa manufactures a range of generic medications and has a production output of about 800 million units per year. With a market share of approximately 4%, Liconsa’s focus on affordability and accessibility makes them a key contributor to the Entacapone supply in Mexico.
9. Laboratorios Stendhal
Laboratorios Stendhal has established a strong foothold in the generic market with a production volume of 600 million units annually, accounting for about 3% of the market share. Their commitment to high-quality generics, including Entacapone, positions them well within the competitive landscape.
10. Grupo Farmacéutico Somar
Grupo Farmacéutico Somar is a prominent manufacturer of generic drugs in Mexico, with a production capacity of approximately 500 million units per year. Their market share is around 2%, and they focus on providing cost-effective solutions for patients requiring Entacapone.
Insights
The Mexican pharmaceutical market, particularly the generic sector, is poised for growth, driven by increased healthcare access and a rising demand for affordable medications. With the generic drug market projected to reach $12 billion by 2028, manufacturers are likely to invest in R&D to enhance product offerings and market penetration. Additionally, the growing prevalence of Parkinson’s disease in the aging population is expected to further boost the demand for Entacapone, providing a significant opportunity for these top manufacturers. As of 2023, the generic pharmaceutical segment is anticipated to maintain a robust CAGR of approximately 7.5%, reflecting ongoing innovations and regulatory support in Mexico.
Related Analysis: View Previous Industry Report
